Home › Companies › LONGBOARD PHARMACEUTICALS INC. › 2023-2024
At LONGBOARD PHARMACEUTICALS INC.'s shareholder meeting held May 23, 2024, in the 2023-2024 proxy season, 51 asset managers reported how they voted on 4 ballot items in their SEC Form N-PX filings, covering 652 separate fund positions. On the most widely held item on that ballot — To elect the two Class III directors named herein to hold office until the Company's 2027… — this item received 23% support of the votes cast (FOR divided by FOR plus WITHHELD, because this ballot offered only for and withhold; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Directors on a for/withhold ballot are elected by plurality, so a nominee can be elected with less than half of the votes cast; no passed or failed outcome is stated here. Source: LONGBOARD PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 24, 2024.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and LONGBOARD PHARMACEUTICALS INC.’s Form 8-K, filed May 24, 2024 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of May 23, 2024: 4 items on LONGBOARD PHARMACEUTICALS INC.’s Form 8-K, filed May 24, 2024: 4 without a stated outcome.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Proxy season: 2023-2024
Explore LONGBOARD PHARMACEUTICALS INC. in the interactive database Compare manager voting policies
These tallies are LONGBOARD PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 24, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Paul J. Sekhri | 6,751,065 | -- | -- | 22,600,014 | 1,365,757 | 23% | Not verified | — |
| Elect Director: Phillip M. Schneider | 24,439,720 | -- | -- | 5,021,497 | 1,255,619 | 83% | Not verified | — |
| 2. The approval of the Officer Exculpation Amendment | 24,766,503 | 4,685,439 | 15,760 | -- | 1,249,134 | 84% | Not verified | — |
| 3. The ratification of the selection of KPMG LLP | 30,707,906 | 2,424 | 6,506 | -- | -- | 99.9% | Not verified | — |
Source: LONGBOARD PHARMACEUTICALS INC., Form 8-K, filed with the SEC on May 24, 2024 — read the filing on EDGAR.
Each item below shows how the 51 asset managers that disclosed a LONGBOARD PHARMACEUTICALS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 4 wordings of this item as funds reported it.
23% Plurality election · of votes cast
Description as filed by funds: To elect the two Class III directors named herein to hold office until the Company's 2027 annual meeting of stockholders: Paul J. Sekhri
LONGBOARD PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Paul J. Sekhri”): 6,751,065 for, 22,600,014 withheld, per its Form 8-K filed May 24, 2024 (Item 5.07). This is a for/withhold election, which is decided by plurality: a nominee does not need a majority of the votes cast to be elected, so no passed or failed outcome is stated here.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 23% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 0 | 0 | 0 | 3,672,716 | Withhold |
| T. Rowe Price | 0 | 0 | 0 | 1,761,492 | Withhold |
| Vanguard | 0 | 0 | 0 | 1,672,639 | Withhold |
| BlackRock | 0 | 0 | 0 | 1,005,022 | Withhold |
| JPMorgan | 0 | 0 | 0 | 395,770 | Withhold |
| Prudential/PGIM | 0 | 0 | 0 | 338,184 | Withhold |
| American Century | 0 | 0 | 0 | 249,824 | Withhold |
| Hartford | 0 | 0 | 0 | 238,976 | Withhold |
| State Street | 55 | 0 | 0 | 126,620 | Withhold |
| Lord Abbett | 0 | 0 | 0 | 123,072 | Withhold |
| John Hancock | 0 | 0 | 0 | 115,814 | Withhold |
| Charles Schwab | 0 | 0 | 0 | 67,641 | Withhold |
| Voya | 0 | 0 | 0 | 52,095 | Withhold |
| SEI | 0 | 0 | 0 | 50,816 | Withhold |
| Goldman Sachs | 0 | 0 | 0 | 48,421 | Withhold |
| Lincoln Financial | 0 | 0 | 0 | 48,044 | Withhold |
| BRIDGEWAY FUNDS INC | 0 | 0 | 0 | 46,333 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 0 | 0 | 0 | 43,681 | Withhold |
| Equitable | 0 | 0 | 0 | 38,814 | Withhold |
| Brighthouse | 0 | 0 | 0 | 38,147 | Withhold |
| MML SERIES INVESTMENT FUND | 0 | 0 | 0 | 36,200 | Withhold |
| DRIEHAUS MUTUAL FUNDS | 0 | 0 | 0 | 25,026 | Withhold |
| New York Life | 0 | 0 | 0 | 14,098 | Withhold |
| RBB FUND, INC. | 0 | 0 | 0 | 14,027 | Withhold |
| AIG/SunAmerica | 0 | 0 | 0 | 12,283 | Withhold |
Fund voting reports, all 50 managers: 55 for, 10,359,033 withheld. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Altium Capital Management LP | 170,000 | 0 | 0 | 0 | For |
Institutional-manager reports, all 1 managers: 170,000 for.
Combines 4 wordings of this item as funds reported it.
83% Majority: yes · of votes cast
Description as filed by funds: To elect the two Class III directors named herein to hold office until the Company's 2027 annual meeting of stockholders: Phillip M. Schneider
LONGBOARD PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Phillip M. Schneider”): 24,439,720 for, 5,021,497 withheld, per its Form 8-K filed May 24, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 83% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 3,672,716 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,761,492 | 0 | 0 | 0 | For |
| Vanguard | 1,672,639 | 0 | 0 | 0 | For |
| BlackRock | 1,005,022 | 0 | 0 | 0 | For |
| JPMorgan | 395,770 | 0 | 0 | 0 | For |
| Prudential/PGIM | 338,184 | 0 | 0 | 0 | For |
| American Century | 0 | 0 | 0 | 249,824 | Withhold |
| Hartford | 238,976 | 0 | 0 | 0 | For |
| State Street | 126,487 | 0 | 0 | 188 | For |
| Lord Abbett | 0 | 0 | 0 | 123,072 | Withhold |
| John Hancock | 109,625 | 0 | 0 | 6,189 | Mixed |
| Charles Schwab | 67,641 | 0 | 0 | 0 | For |
| Voya | 52,095 | 0 | 0 | 0 | For |
| SEI | 50,816 | 0 | 0 | 0 | For |
| Goldman Sachs | 0 | 0 | 0 | 48,421 | Withhold |
| Lincoln Financial | 48,044 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 0 | 0 | 0 | 46,333 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 43,681 | 0 | 0 | 0 | For |
| Equitable | 20,680 | 0 | 0 | 18,134 | Mixed |
| Brighthouse | 19,981 | 0 | 0 | 18,166 | Mixed |
| MML SERIES INVESTMENT FUND | 36,200 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 0 | 0 | 0 | 25,026 | Withhold |
| New York Life | 14,098 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 0 | 0 | 0 | 14,027 | Withhold |
| AIG/SunAmerica | 0 | 0 | 0 | 12,283 | Withhold |
Fund voting reports, all 50 managers: 9,746,027 for, 613,061 withheld. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Altium Capital Management LP | 170,000 | 0 | 0 | 0 | For |
Institutional-manager reports, all 1 managers: 170,000 for.
Combines 3 wordings of this item as funds reported it.
84% Majority: yes · of votes cast
Description as filed by funds: To approve an amendment to the Company's Amended and Restated Certificate of Incorporation to limit the liability of officers of the Company to the maximum extent permitted by law as permitted pursuant to Section 102(b)(7) of the Delaware General Corporation Law.
LONGBOARD PHARMACEUTICALS INC.’s own tally for this item (“2. The approval of the Officer Exculpation Amendment”): 24,766,503 for, 4,685,439 against, per its Form 8-K filed May 24, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 84% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 3,672,716 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,761,492 | 0 | 0 | 0 | For |
| Vanguard | 1,672,639 | 0 | 0 | 0 | For |
| BlackRock | 1,005,022 | 0 | 0 | 0 | For |
| JPMorgan | 0 | 395,770 | 0 | 0 | Against |
| Prudential/PGIM | 0 | 338,184 | 0 | 0 | Against |
| American Century | 249,824 | 0 | 0 | 0 | For |
| Hartford | 238,976 | 0 | 0 | 0 | For |
| State Street | 126,658 | 17 | 0 | 0 | For |
| Lord Abbett | 123,072 | 0 | 0 | 0 | For |
| John Hancock | 115,814 | 0 | 0 | 0 | For |
| Charles Schwab | 67,641 | 0 | 0 | 0 | For |
| Voya | 52,095 | 0 | 0 | 0 | For |
| SEI | 0 | 50,816 | 0 | 0 | Against |
| Goldman Sachs | 48,421 | 0 | 0 | 0 | For |
| Lincoln Financial | 13,300 | 34,744 | 0 | 0 | Mixed |
| BRIDGEWAY FUNDS INC | 46,333 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 43,681 | 0 | 0 | 0 | For |
| Equitable | 38,814 | 0 | 0 | 0 | For |
| Brighthouse | 38,147 | 0 | 0 | 0 | For |
| MML SERIES INVESTMENT FUND | 36,200 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 25,026 | 0 | 0 | 0 | For |
| New York Life | 14,098 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 14,027 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 12,283 | 0 | 0 | 0 | For |
Fund voting reports, all 50 managers: 9,529,979 for, 829,109 against. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Altium Capital Management LP | 170,000 | 0 | 0 | 0 | For |
Institutional-manager reports, all 1 managers: 170,000 for.
Combines 2 wordings of this item as funds reported it.
99.9% Majority: yes · of votes cast
Description as filed by funds: To ratify the selection by the Audit Committee of the Board of Directors of KPMG LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024.
LONGBOARD PHARMACEUTICALS INC.’s own tally for this item (“3. The ratification of the selection of KPMG LLP”): 30,707,906 for, 2,424 against, per its Form 8-K filed May 24, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 3,672,716 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,761,492 | 0 | 0 | 0 | For |
| Vanguard | 1,672,639 | 0 | 0 | 0 | For |
| BlackRock | 1,005,022 | 0 | 0 | 0 | For |
| JPMorgan | 395,770 | 0 | 0 | 0 | For |
| Prudential/PGIM | 338,184 | 0 | 0 | 0 | For |
| American Century | 249,824 | 0 | 0 | 0 | For |
| Hartford | 238,976 | 0 | 0 | 0 | For |
| State Street | 126,675 | 0 | 0 | 0 | For |
| Lord Abbett | 123,072 | 0 | 0 | 0 | For |
| John Hancock | 115,814 | 0 | 0 | 0 | For |
| Charles Schwab | 67,641 | 0 | 0 | 0 | For |
| Voya | 52,095 | 0 | 0 | 0 | For |
| SEI | 50,816 | 0 | 0 | 0 | For |
| Goldman Sachs | 48,421 | 0 | 0 | 0 | For |
| Lincoln Financial | 48,044 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 46,333 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 43,681 | 0 | 0 | 0 | For |
| Equitable | 38,814 | 0 | 0 | 0 | For |
| Brighthouse | 38,147 | 0 | 0 | 0 | For |
| MML SERIES INVESTMENT FUND | 36,200 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 25,026 | 0 | 0 | 0 | For |
| New York Life | 14,098 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 14,027 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 12,283 | 0 | 0 | 0 | For |
Fund voting reports, all 50 managers: 10,359,088 for. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Altium Capital Management LP | 170,000 | 0 | 0 | 0 | For |
Institutional-manager reports, all 1 managers: 170,000 for.
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 38,880,054 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 9.45% |
| 2 | T. Rowe Price | 4.53% |
| 3 | Vanguard | 4.30% |
| 4 | BlackRock | 2.58% |
| 5 | JPMorgan | 1.02% |
| 6 | Prudential/PGIM | 0.87% |
| 7 | American Century | 0.64% |
| 8 | Hartford | 0.61% |
| 9 | State Street | 0.33% |
| 10 | Lord Abbett | 0.32% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Altium Capital Management LP | 0.44% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| FMR LLC | 11.59% | DEF14A |
| Arena Pharmaceuticals, Inc. | 10.23% | 13D |
| Entities affiliated with Zone II Healthcare Holdings, LLC | 8.75% | DEF14A |
| RA Capital Healthcare Fund, L.P. | 7.90% | DEF14A |
| Entities affiliated with Cormorant Asset Management, LP | 6.05% | DEF14A |
| T. Rowe Price | 5.70% | 13F |
| Wellington Management | 5.49% | 13F |
| Point72 | 3.54% | 13F |
| Kevin Lind | 2.39% | DEF14A |
| State Street | 1.67% | 13F |
Percentages above are of 38,880,054 shares outstanding, as reported by LONGBOARD PHARMACEUTICALS INC. on its Form 10-Q dated April 30, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from LONGBOARD PHARMACEUTICALS INC.’s 10-Q dated April 30, 2024. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
LONGBOARD PHARMACEUTICALS INC. proxy season coverage: 2023-2024 (this page).
proxyvotesnow.com, “LONGBOARD PHARMACEUTICALS INC. 2024 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/longboard-pharmaceuticals-inc/2024 (version of November 9, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.